News
-
PHT Corporation Patents ‘Time Travel’ For Clinical Research
12/11/2012
It’s now possible for clinical trial researchers to control time, thanks to PHT Corporation’s patented Time Travel technology.PHT is the world’s leading provider of systems used to collect patient-driven eData for clinical research.
-
Express Diagnostics Int’l, Inc. Appoints Blinded Diagnostics To Offer Drugs Of Abuse And Alcohol Testing For Use In Pharmaceutical Clinical Trials
12/6/2012
Blinded Diagnostics recently announced the expansion of their diagnostic product portfolio with the addition of an extensive line of screening tests for drugs of abuse and alcohol from Express Diagnostics Int’l, Inc. (EDI) of Blue Earth, MN.
-
Peregrine Pharmaceuticals Announces Significant Progress In Advancing Its Cotara Program Into A Pivotal Phase III Trial
12/5/2012
Peregrine Pharmaceuticals (
NASDAQ : PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it has made significant progress in advancing its Cotara program into late-stage development through its agreement with the U.S. -
Thomson Reuters Empowers Drug Development And Clinical Professionals To Develop Better, Faster Clinical Trials With Best-In-Class Intelligence Solution
12/5/2012
The IP & Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals, recently announced a preview of its newest intelligence solution, Thomson Reuters Cortellis for Clinical Trials Intelligence.
-
A Collaboration For More Effective Centralized Cardiac Safety Services
12/3/2012
Spaulding Clinical Research Announces Collaboration with Blinded Diagnostics for centralized cardiac safety services for select pharmaceutical clients.
-
Spaulding Clinical Research Announces Collaboration With Blinded Diagnostics For Centralized Cardiac Safety Services For Select Pharmaceutical Clients
12/3/2012
Spaulding Clinical Research has agreed to offer ECG services using the new Spaulding webECG Diagnostic ECG Management system for late stage clinical trials through Blinded Diagnostics.
-
Immunovative Announces Regulatory Clearance To Conduct A Phase II/III Clinical Trial In Advanced Metastatic Breast Cancer For AlloStim™
11/29/2012
Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) announces today that Immunovative Therapies, Ltd. ("ITL") has been granted regulatory clearance from Thailand authorities to advance its lead AlloStim™ immunotherapy product candidate to the Phase II/III clinical development stage in advanced metastatic breast cancer.
-
Phase 2b Data Of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved In Up To 85% Of Treatment-Naive Patients
11/10/2012
Final Phase 2b data from Boehringer Ingelheim's interferon (IFN)-free Phase 2b SOUND-C2 study showed that up to 85 percent of genotype 1b (GT1b) hepatitis C (HCV) patients achieved sustained virologic response (SVR or viral cure) 12 and 24 weeks after the end of treatment with the investigational treatment regimen of faldaprevir (BI 201335) and BI 207127, in combination with ribavirin (RBV)
-
Zafgen Announces Initiation Of Phase 2a Clinical Development With Beloranib In Obesity
11/6/2012
Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that it has initiated Phase 2a clinical testing of beloranib.
-
Extraneous Data Collected In Clinical Trials Cost Drug Developers $4B To $6B Annually, According To Tufts Center For The Study Of Drug Development
11/6/2012
One out of every five procedures performed during later stage clinical trials collects extraneous data and costs drug developers more than $1 million per trial, a newly completed study by the Tufts Center for the Study of Drug Development has found.